Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2061168 | 1.00 | TSHR (0.40) | TSHRALDH1A1SMN1; SMN2USP2LMNA | |
| SCHEMBL24012349 | 1.00 | TSHR (0.40) | TSHRALDH1A1SMN1; SMN2USP2LMNA | |
| SCHEMBL2790764 | 0.97 | TSHR (0.37) | TSHRALDH1A1SMN1; SMN2USP2LMNA | |
| SCHEMBL15774512 | 0.92 | — | — | |
| SCHEMBL14152208 | 0.87 | — | — | |
| SCHEMBL20198601 | 0.80 | TSHR (0.56) | TSHRALDH1A1SMN1; SMN2USP2LMNA | |
| SCHEMBL20104809 | 0.80 | TSHR (0.56) | TSHRALDH1A1SMN1; SMN2USP2LMNA | |
| SCHEMBL21119408 | 0.80 | — | — | |
| SCHEMBL498155 | 0.80 | TSHR (0.56) | TSHRALDH1A1SMN1; SMN2USP2LMNA | |
| Hydrochloric Acid SCHEMBL7609840 | 0.78 | TSHR (0.54) | TSHRALDH1A1SMN1; SMN2USP2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190202810-A1 | CARBOCYCLIC PROLINAMIDE DERIVATIVES | Orion Ophthalmology LLC (US) | 2019-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190202810-A1 | CARBOCYCLIC PROLINAMIDE DERIVATIVES | HTRA1, ADCYAP1R1, HTRA2 | TSHR 1454/4885ALDH1A1 271/4885SMN1; SMN2 1713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.